Sandbox Reserved 1652: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 78: Line 78:
== Implication of TRPV1 in the treatment of pain ==
== Implication of TRPV1 in the treatment of pain ==


In 2011 Qutenza (NeurogesX) patch containing 8% of capsaicin has been markered in France and indicated in the [https://en.wikipedia.org/wiki/Neuropathic_pain neuropathic pain].  
Capsaicin stimulates and desensitizes several receptors from the A(delta) and C fibers. This phenomenon will release inflammatory neuropeptides.
Capsaicin assists the entry of Ca2+ in the neuron by a nonspecific membrane.
TRPV1 can be activated by heat and voltage variation.
This receptor exists under 3 different forms and ethanol is able to activate this receptor.
In 2011 Qutenza (NeurogesX) patch containing 8% of capsaicin has been marketed in France and indicated in the [https://en.wikipedia.org/wiki/Neuropathic_pain neuropathic pain].  
The absorption through the skin of these creams generated partial desensitization of the nerve endings. This is the cause of a decrease in painful sensations.<ref name="TRPV1 dans les neuropathies douloureuses - Des modèles animaux aux perspectives thérapeutiques">A. Danigo, L. Magy, et C. Demiot, « TRPV1 dans les neuropathies douloureuses - Des modèles animaux aux perspectives thérapeutiques », médecine/sciences, vol. 29, no 6‑7, Art. no 6‑7, juin 2013, doi: 10.1051/medsci/2013296012.</ref>
The absorption through the skin of these creams generated partial desensitization of the nerve endings. This is the cause of a decrease in painful sensations.<ref name="TRPV1 dans les neuropathies douloureuses - Des modèles animaux aux perspectives thérapeutiques">A. Danigo, L. Magy, et C. Demiot, « TRPV1 dans les neuropathies douloureuses - Des modèles animaux aux perspectives thérapeutiques », médecine/sciences, vol. 29, no 6‑7, Art. no 6‑7, juin 2013, doi: 10.1051/medsci/2013296012.</ref>
 
[https://en.wikipedia.org/wiki/Capsazepine] is a synthetic competitive antagonist of this receptor which is currently used to study TRPV1 function.
Many laboratories are conducting clinical studies on oral TRPV1 antagonists: GlaxoSmithKline, Amgen, Merk-Neurogen, Abbot, Eli-Lilly-Glenmark, AstraZeneca and Japan Tobacco. The major problem with these pain relievers is the [https://en.wikipedia.org/wiki/Hyperthermia hyperthermia] generated in humans. These effects caused these studies to be stopped in phase I.<ref name="TRPV1 dans les neuropathies douloureuses - Des modèles animaux aux perspectives thérapeutiques"/>
Many laboratories are conducting clinical studies on oral TRPV1 antagonists: [https://fr.wikipedia.org/wiki/GlaxoSmithKline], [https://en.wikipedia.org/wiki/Amgen], [https://en.wikipedia.org/wiki/Merck_%26_Co.]-Neurogen, [https://en.wikipedia.org/wiki/Abbott_Laboratories], [https://en.wikipedia.org/wiki/Eli_Lilly_and_Company], [https://en.wikipedia.org/wiki/AstraZeneca] and [https://en.wikipedia.org/wiki/Japan_Tobacco]. Nowadays at least seven orally active TRPV1 antagonist substances successfully went for clinical development and the laboratories cited before all completed phase I trials . However some of them have stopped their researches at phase II trials by unknown reason as GlaxoSmithKline  <ref name="SB-705498">The National Center for Advancing Translational Sciences «SB-705498 » , https://drugs.ncats.io/drug/T74V9O0Y2W, (Consulté le: déc. 29, 2021)</ref>
 
with the antagonist SB-705498 or Lilly with the antagonist GRC 6211 <ref name="Further Clinical Trials in Osteoarthritis Pain Suspended for GRC 6211">Calisha Myers, 24 oct. 2008, «Further Clinical Trials in Osteoarthritis Pain Suspended for GRC 6211 » , https://www.fiercebiotech.com/biotech/further-clinical-trials-osteoarthritis-pain-suspended-for-grc-6211, (Consulté le: déc. 29, 2021)</ref>
The research on the antagonists of TRPV1 remains encouraging. <ref name="TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: Compounds’ pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development">A. Garami,E. Pakai,H. A. McDonald,R. M. Reilly,A. Gomtsyan,J. J. Corrigan,E. Pinter,D. X. D. Zhu,S. G. Lehto,N. R. Gavva,P. R. Kym,A. A. Romanovsky, 20 jan. 2018, «TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: Compounds’ pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development » ,https://onlinelibrary.wiley.com/doi/full/10.1111/apha.13038
, (Consulté le: déc. 29, 2021)</ref>





Revision as of 09:56, 30 December 2021

This Sandbox is Reserved from 26/11/2020, through 26/11/2021 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1643 through Sandbox Reserved 1664.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • Click the 3D button (when editing, above the wikitext box) to insert Jmol.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

The Transient Receptor Potential cation channel subfamily V member 1 TRPV1

Structure of TRPV1 in complex with capsazepine, determined in lipid nano disc, capsazepine is a synthetic antagonist of capsaicin

Drag the structure with the mouse to rotate

References